Effect of Fexofenadine as an Adjunct to DPCP in Non-Atopic Patients with Alopecia Areata: A Randomized Clinical TrialSolmaz Soltanahmadi* and Maryam Akhyani
Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
- *Corresponding Author:
- Solmaz Soltanahmadi
Razi Hospital, Tehran, Iran
E-mail: [email protected]
Received date: July 30, 2012; Accepted date: September 06, 2012; Published date: September 13, 2012
Citation: Soltanahmadi S, Akhyani M (2012) Effect of Fexofenadine as an Adjunct to DPCP in Non-Atopic Patients with Alopecia Areata: A Randomized Clinical Trial. J Clin Exp Dermatol Res 3:155. doi: 10.4172/2155-9554.1000155
Copyright: © 2012 Soltanahmadi S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Introduction: In this study the effect of fexofenadine as an adjunct to diphenylcyclopropenone (DPCP) in non-atopic patients with Alopecia areata (AA) is investigated.
Patients and methods: Prospectively 100 patients with AA having hair loss of more than 25% of the scalp are randomly divided into two groups in group A patients received topical DPCP plus oral fexofenafine, in group B patients received only topical DPCP.
Results: Regrowth in group A was better than group B but this was not statistically significant. Eczematous reaction and pruritus was significantly lower in group A than in group B.
Discussion: Fexofenadine seems to be of no benefit in patients without underlying contributing situation. Therefore, it can be added to conventional regimen in order to enhance the compliance of patients by reducing discomfort of DPCP treatment.